$150 Billion Weight-Loss Drug Market Temptation: Novo Nordisk Expands Production Against the Tide
Facing Eli Lilly’s competition and short-term sales slumps, can NVO reclaim its GLP-1 dominance in the $150B market?
Are you bullish on its long-term bet, or is LLY a better pick?
Share your thoughts on the weight-loss drug race below!
To consolidate its position in the global weight-loss drug market, Danish pharmaceutical giant $Novo-Nordisk A/S(NVO)$ is accelerating capacity expansion. According to local media reports on Monday, the company will invest €432 million (approximately $507 million) to upgrade its factory in Athlone, Ireland, to produce its blockbuster weight-loss drug Wegovy for markets outside the United States. A company spokesperson has confirmed the scale of this investment. The upgrade will significantly enhance its production capacity for current and future obesity and diabetes drugs, ensuring stable supply of key products.
Mounting Market Challenges: Giant Faces Dual Pressures
This move comes as Novo Nordisk encounters a cold spell in the capital market. Over the past 12 months, the healthcare company’s stock price has plummeted by approximately 60%. Pessimistic earnings guidance and widespread investor concerns about its ability to maintain an edge in the long-term showdown with major competitor Eli Lilly (LLY) have collectively shaped the current market sentiment. Although Novo Nordisk has an approved GLP-1 weight-loss drug, the market widely fears that its first-mover advantage will be difficult to sustain with the launch of Eli Lilly’s similar products.
In fact, Eli Lilly has also laid out production capacity in Ireland and announced an $800 million investment in 2024 to expand its factory in Cork, primarily for manufacturing the active ingredients of weight-loss drugs—indicating a full-scale showdown between the two giants in terms of capacity and market share. Approximately two years ago, Novo Nordisk abandoned plans to build a factory near Dublin and laid off employees at the Athlone plant in September last year; this large-scale investment can also be seen as an adjustment and escalation of its strategy.
Short-Term Performance Slump: Caught Between Competition and Combination Drugs
The challenges facing Novo Nordisk are concrete and severe. The company expects adjusted sales to decline by 5% to 13% this year, with operating profits seeing a similar drop. This worrying earnings outlook directly triggered a recent sell-off of its stock. In addition to competition from legitimate manufacturers like Eli Lilly, compound formulations of popular drugs produced by some pharmacies have also diverted its sales. Last month, Novo Nordisk filed a lawsuit against Hims & Hers Health, accusing it of selling unauthorized drugs that infringe on patents. Successfully curbing these compound formulations—usually allowed for sale only during drug shortages—will undoubtedly boost the company’s growth this year.
Looking Long-Term: The GLP-1 Track Still Holds Great Promise
Despite the short-term bleak outlook, Novo Nordisk’s fundamentals remain solid in the long run. Investing in stocks is essentially a bet on a company’s long-term value, and excessive focus on short-term fluctuations may come at a high cost. Currently, Novo Nordisk may face severe challenges, but its status as a core participant in the GLP-1 drug market remains unshaken. Even if competitors’ products are superior in certain aspects, the global GLP-1 drug market is estimated to exceed $150 billion by 2035. The huge market space is sufficient to accommodate multiple successful enterprises, and Novo Nordisk, with its first-mover advantage and continuous investment, still has the ability to capture a substantial market share in the future.
For SG users only, Welcome to open a CBA today and enjoy access to a trading limit of up to SGD 20,000 with unlimited trading on SG, HK, and US stocks, as well as ETFs.
🎉Cash Boost Account Now Supports 35,000+ Stocks & ETFs – Greater Flexibility Now
Find out more here.
Complete your first Cash Boost Account trade with a trade amount of ≥ SGD1000* to get SGD 688 stock vouchers*! The trade can be executed using any payment type available under the Cash Boost Account: Cash, CPF, SRS, or CDP.
Other helpful links:
-
💰Join the TB Contra Telegram Group to Get $10 Trading Vouchers Now🎉
-
How to open a CBA. How to link your CDP account. Other FAQs on CBA. Cash Boost Account Website.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
